Stifel Cautious On Aurora Cannabis Given ‘Lack Of A Definitive Strategy’ In US

Cannabis stocks are getting more and more attention from Wall Street these days, and Aurora Cannabis Inc (NYSE: ACB) received its first coverage from Stifel on Thursday.

The Analyst

Stifel analyst W. Andrew Carter initiated coverage of Aurora with a Hold rating and a C$10 ($7.47) price target.

The Thesis

Despite impressive growth numbers projected in the next several years, Carter said Aurora’s international medical-use growth opportunities are limited outside of Canada and Germany.

“We are cautious on Aurora in the near-term given the company’s reliance on the capital markets to execute upon its near-term business plans, the lack of a definitive strategy for entering the U.S. market, and we believe …

Full story available on Benzinga.com

More Stifel Cautious On Aurora Cannabis Given 'Lack Of A Definitive Strategy' In US